Почетна › Difuzni veliki B-ćelijski limfom › Орегон
Kliničke studije za Difuzni veliki B-ćelijski limfom u državi Орегон
15 studija za Difuzni veliki B-ćelijski limfom traži učesnike na lokacijama u državi Орегон.
Gradovi u državi Орегон
Zvanični tekst studije (na engleskom)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001), Eugene
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Oncology Associates of Oregon, P.C, Eugene
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06806033Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Providence Hood River Memorial Hospital, Hood River
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06649812A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Oregon Health & Science University (OHSU), Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Oregon Health and Science University ( Site 1004), Portland
Тражи се учесникФаза 1/2
6 Months – 25 Years · Оба пола · Ажурирано 30. 10. 2026. · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06500273Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05890352Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
Тражи се учесникФаза 1/2
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT05633615Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT06784167Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Oregon Health and Science University Knight Cancer Institute, Portland
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 5. 8. 2026. · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Oregon Health and Science University Knight Cancer Institute, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 7. 2026. · NCT04792489Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
- OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 7. 7. 2026. · NCT06249191A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 10. 2025. · NCT05780034Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.